BridgeBio’s nice week, Moderna’s fall

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and writer of the e-newsletter Adam’s Biotech Scorecard. You may attain Adam on Sign at stataf.54.

Has BridgeBio’s enterprise mannequin labored? How are executives at Moderna coping with the corporate’s droop? And who will the hosts gown up as for Halloween?

We talk about all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We convey on BridgeBio CEO Neil Kumar to debate the corporate’s optimistic Section 3 readouts and our colleague Jason Mast to debate Moderna’s struggles following its Covid-19 vaccine increase.

We additionally chat concerning the information this week, together with Novo Nordisk’s takeover bid for biotech firm Metsera and troubles within the discipline of genetic medicines.

To be taught extra on BridgeBio’s optimistic information, go right here; to learn the function on Moderna, go right here; for extra on Novo’s takeover bid, go right here; and for extra on Intellia’s resolution to pause its gene-editing trials, go right here.

Make certain to join “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.